SEC Form 4 · accession 0000920465-18-000002
LA JOLLA PHARMACEUTICAL CO · LJPC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura L. Douglass
Director
Period of report
Dec 29, 2017
Accepted (ET)
Jan 3, 2018 · 9:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920465
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 29, 2017 | M | 6,000 | $10.84 | A | 6,000 | D | |
| Common Stock | Dec 29, 2017 | M | 4,000 | $6.00 | A | 10,000 | D | |
| Common StockF1 | Dec 29, 2017 | S | 10,000 | $32.3208 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $10.84 | Dec 29, 2017 | M | 6,000 | D | — | Apr 3, 2024 | Common Stock | 6,000 | 0 | D |
| Stock Option (Right to Buy)F3 | $6.00 | Dec 29, 2017 | M | 4,000 | D | — | Nov 21, 2023 | Common Stock | 4,000 | 14,000 | D |
Explanation of responses
- F1Represents the average sale price, with individual sale prices ranging from $32.29 to $32.49 per share. The reporting person will provide the Staff of the Securities and Exchange Commission or a shareholder with individual sales price information, if requested.
- F2This option represents a right to purchase a total of 6,000 shares of the Issuer's Common Stock, one third of which shall be fully vested and exercisable on April 3, 2015, with the remaining 4,000 shares vesting quarterly thereafter over the next two years.
- F3These options represent a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one quarter of which shall be fully vested and exercisable on October 14, 2014, with the remaining 13,500 shares vesting monthly thereafter over the next three years in 36 equal increments of 375 shares.